1.Characteristics of New Estrogen Biosensor Employing Taste Principles.
Soon Bae KWON ; Cil Han LEE ; Kyung Nyun KIM
International Journal of Oral Biology 2011;36(2):103-108
Measurement of estrogen concentration in bio-samples are very important for differential diagnosis of various disease or evaluation of health status. However, it is difficult to collect immediate data of estrogen concentration because they are measured by radioimmunoassay or chromatography which need time- and cost-consuming sample pre-treatment. This study was performed for development of new estrogen biosensor employing taste principles, and for evaluation of cross reactivity between various steroid hormones. Gene sequence of ligand binding domain of alpha-human estrogen receptor (amino acid 302-553; hER-LBD) was cloned from human breast cancer cell line. The proteins of hER-LBD were produced by T7-E.coli expression system, and isolated by chromatography. hER-LBD were coated on the gold plated quartz crystal (AT-cut 9MHz), and resonance frequencies were measured by universal frequency counter. Estradiol, progesterone, testosterone, and aldosterone were used for cross reactivity of the hER-LBD. We also monitored influences of pH change in resonance frequency. The resonance frequencies of hER-LBD coated quartz crystal were decreased during increase of estrogen concentration from 15 microg/mL to 50 microg/mL. However, similar steroid hormones, progesterone and aldosterone, did not elicit the change in resonance frequency. Testosterone evoke weak change in resonance frequency. The new estrogen biosensor was more sensitive in pH 7.2 than in pH 7.6. These results suggest that hER-LBD coated quartz crystal biosensor is a probable estrogen biosensor.
Aldosterone
;
Biosensing Techniques
;
Breast Neoplasms
;
Cell Line
;
Chromatography
;
Clone Cells
;
Collodion
;
Diagnosis, Differential
;
Endocrine Disruptors
;
Estradiol
;
Estrogens
;
Humans
;
Hydrogen-Ion Concentration
;
Organothiophosphorus Compounds
;
Progesterone
;
Proteins
;
Quartz
;
Radioimmunoassay
;
Testosterone
2.Type II and III Taste Bud Cells Preferentially Expressed Kainate Glutamate Receptors in Rats.
Sang Bok LEE ; Cil Han LEE ; Se Nyun KIM ; Ki Myung CHUNG ; Young Kyung CHO ; Kyung Nyun KIM
The Korean Journal of Physiology and Pharmacology 2009;13(6):455-460
Glutamate-induced cobalt uptake reveals that non-NMDA glutamate receptors (GluRs) are present in rat taste bud cells. Previous studies involving glutamate induced cobalt staining suggest this uptake mainly occurs via kainate type GluRs. It is not known which of the 4 types of taste bud cells express subunits of kainate GluR. Circumvallate and foliate papillae of Sprague-Dawley rats (45~60 days old) were used to search for the mRNAs of subunits of non-NMDA GluRs using RT-PCR with specific primers for GluR1-7, KA1 and KA2. We also performed RT-PCR for GluR5, KA1, PLCbeta2, and NCAM/SNAP 25 in isolated single cells from taste buds. Taste epithelium, including circumvallate or foliate papilla, express mRNAs of GluR5 and KA1. However, non-taste tongue epithelium expresses no subunits of non-NMDA GluRs. Isolated single cell RT-PCR reveals that the mRNAs of GluR5 and KA1 are preferentially expressed in Type II and Type III cells over Type I cells.
Animals
;
Cobalt
;
Epithelium
;
Glutamic Acid
;
Kainic Acid
;
Rats
;
Rats, Sprague-Dawley
;
Receptors, Glutamate
;
Receptors, Kainic Acid
;
RNA, Messenger
;
Taste Buds
;
Tongue
3.Impact of the beta-1 adrenergic receptor polymorphism on tolerability and efficacy of bisoprolol therapy in Korean heart failure patients: association between beta adrenergic receptor polymorphism and bisoprolol therapy in heart failure (ABBA) study.
Hae Young LEE ; Wook Jin CHUNG ; Hui Kyung JEON ; Hong Seog SEO ; Dong Ju CHOI ; Eun Seok JEON ; Jae Joong KIM ; Joon Han SHIN ; Seok Min KANG ; Sung Cil LIM ; Sang Hong BAEK
The Korean Journal of Internal Medicine 2016;31(2):277-287
BACKGROUND/AIMS: We evaluated the association between coding region variants of adrenergic receptor genes and therapeutic effect in patients with congestive heart failure (CHF). METHODS: One hundred patients with stable CHF (left ventricular ejection fraction [LVEF] < 45%) were enrolled. Enrolled patients started 1.25 mg bisoprolol treatment once daily, then up-titrated to the maximally tolerable dose, at which they were treated for 1 year. RESULTS: Genotypic analysis was carried out, but the results were blinded to the investigators throughout the study period. At position 389 of the beta-1 adrenergic receptor gene (ADRB1), the observed minor Gly allele frequency (Gly389Arg + Gly389Gly) was 0.21, and no deviation from Hardy-Weinberg equilibrium was observed in the genotypic distribution of Arg389Gly (p = 0.75). Heart rate was reduced from 80.8 +/- 14.3 to 70.0 +/- 15.0 beats per minute (p < 0.0001). There was no significant difference in final heart rate across genotypes. However, the Arg389Arg genotype group required significantly more bisoprolol compared to the Gly389X (Gly389Arg + Gly389Gly) group (5.26 +/- 2.62 mg vs. 3.96 +/- 2.05 mg, p = 0.022). There were no significant differences in LVEF changes or remodeling between two groups. Also, changes in exercise capacity and brain natriuretic peptide level were not significant. However, interestingly, there was a two-fold higher rate of readmission (21.2% vs. 10.0%, p = 0.162) and one CHF-related death in the Arg389Arg group. CONCLUSIONS: The ADRB1 Gly389X genotype showed greater response to bisoprolol than the Arg389Arg genotype, suggesting the potential of individually tailoring beta-blocker therapy according to genotype.
Adrenergic beta-1 Receptor Antagonists/adverse effects/*therapeutic use
;
Adult
;
Aged
;
Bisoprolol/adverse effects/*therapeutic use
;
Female
;
Gene Frequency
;
Genotype
;
Heart Failure/diagnosis/*drug therapy/*genetics/physiopathology
;
Heart Rate/drug effects
;
Humans
;
Male
;
Maximum Tolerated Dose
;
Middle Aged
;
Pharmacogenomic Testing
;
Phenotype
;
*Polymorphism, Genetic
;
Precision Medicine
;
Receptors, Adrenergic, beta-1/*drug effects/*genetics
;
Republic of Korea
;
Stroke Volume/drug effects
;
Time Factors
;
Treatment Outcome
;
Ventricular Function, Left/drug effects
;
Ventricular Remodeling/drug effects